Lupisulin M 30 Injection 100IU/ml is a combination insulin preparation containing 70% insulin isophane (NPH insulin) and 30% human insulin, designed for the management of diabetes mellitus requiring insulin therapy. This biphasic insulin formulation provides both intermediate and short-acting insulin effects, facilitating improved glycemic control by addressing both basal and prandial insulin requirements. Insulin isophane acts as an intermediate-acting insulin, offering prolonged glucose-lowering activity, while human insulin provides rapid onset to control postprandial glucose excursions. Lupisulin M 30 is indicated for adult and pediatric patients with type 1 or type 2 diabetes mellitus when diet, exercise, and oral hypoglycemic agents alone do not achieve adequate glycemic control. The injection is administered subcutaneously, with dosing individualized based on patient needs, blood glucose monitoring, and glycemic targets. Careful titration is essential to minimize the risk of hypoglycemia, the most common adverse effect associated with insulin therapy. Patients should be educated on proper injection techniques, storage conditions, and recognition of hypoglycemia symptoms. Lupisulin M 30 should be used under medical supervision, with regular monitoring of blood glucose and HbA1c levels to optimize therapeutic outcomes and prevent diabetes-related complications.